Bempedoic acid/ezetimibe - Esperion Therapeutics

Drug Profile

Bempedoic acid/ezetimibe - Esperion Therapeutics

Alternative Names: ETC 1002/Ezetimibe - Esperion Therapeutics; Ezetimibe/bempedoic acid - Esperion Therapeutics

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Esperion Therapeutics
  • Class Antihyperlipidaemics; Azetidines; Dicarboxylic acids; Fatty acids; Fluorobenzenes; Propanols; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; ATP citrate (pro S) lyase inhibitors; Cholesterol absorption inhibitors; NPC1L1 protein inhibitors; Peroxisome proliferator-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hypercholesterolaemia

Most Recent Events

  • 07 Nov 2017 Esperion Therapeutics expects the regulatory approval of bempedoic acid/ezetimibe in the first quarter of 2020
  • 07 Nov 2017 Esperion Therapeutics intends to submit a NDA for bempedoic acid/ezetimibe by the first quarter of 2019
  • 23 Oct 2017 Esperion Therapeutics initiates a phase III trial for Hypercholesterolaemia in USA (NCT03337308; 9226801)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top